Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CTSS | P25774 | 7/20 | 0.47 |
| ▸ | CTSK | P43235 | 7/20 | 0.47 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 5/20 | 0.42 |
| ▸ | PPARG | P37231 | 4/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.42 |
| ▸ | SUCNR1 | Q9BXA5 | 2/20 | 0.41 |
| ▸ | PPARD | Q03181 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13170309 | 0.89 | CAPN1 (0.47) | MEN1GAAKMT2ACTSSCTSK | |
| SCHEMBL25715929 | 0.88 | CAPN1 (0.53) | MEN1GAAKMT2ACTSSCTSK | |
| SCHEMBL13170285 | 0.88 | CAPN1 (0.53) | MEN1GAAKMT2ACTSSCTSK | |
| SCHEMBL18975551 | 0.88 | CAPN1 (0.53) | MEN1GAAKMT2ACTSSCTSK | |
| SCHEMBL15512548 | 0.85 | MEN1 (0.54) | MEN1GAAKMT2ACTSSCTSK | |
| SCHEMBL26620271 | 0.84 | MEN1 (0.51) | MEN1GAAKMT2ACTSSCTSK | |
| SCHEMBL26620267 | 0.84 | MEN1 (0.51) | MEN1GAAKMT2ACTSSCTSK | |
| SCHEMBL1003435 | 0.83 | MEN1 (0.61) | MEN1GAAKMT2ACTSSCTSK | |
| SCHEMBL2581187 | 0.83 | PPARA (0.48) | CTSSCTSKCAPN1CTSLCTSB | |
| SCHEMBL18281226 | 0.83 | MEN1 (0.61) | MEN1GAAKMT2ACTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150133364-A1 | DIPEPTOID PRODRUGS AND THEIR USE | BAYER IP GMBH (DE) | 2015-05-14 | — | — | US | disclosed |
| US-8957017-B2 | Dipeptoid prodrugs and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-02-17 | — | — | US | disclosed |
| US-20140206879-A1 | DIPEPTOID PRODRUGS AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-07-24 | — | — | US | disclosed |
| US-8703696-B2 | Dipeptoid prodrugs and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-04-22 | — | — | US | disclosed |
| EP-2185552-B1 | DIPEPTOID PRODRUGS AND THE USE THEREOF | BAYER IP GMBH (DE) | 2014-03-12 | — | — | EP | disclosed |
| EP-2185552-B1 | DIPEPTOID PRODRUGS AND THE USE THEREOF | BAYER IP GMBH (DE) | 2014-03-12 | — | — | EP | disclosed |
| US-20110294718-A1 | DIPEPTOID PRODRUGS AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206879-A1 | DIPEPTOID PRODRUGS AND THEIR USE | DPP4, DPP3, DPP7 | MEN1 2264/4885GAA 1797/4885KMT2A 2842/4885 |
| US-20110294718-A1 | DIPEPTOID PRODRUGS AND THE USE THEREOF | DPP4, DPP3, DPP7 | MEN1 2035/4885GAA 1868/4885KMT2A 3076/4885 |
| US-20150133364-A1 | DIPEPTOID PRODRUGS AND THEIR USE | DPP4, DPP3, DPP7 | MEN1 2264/4885GAA 1797/4885KMT2A 2842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.